Literature DB >> 8695761

Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis.

C Miller1, J Rivier.   

Abstract

The development of relatively non-compressible supporting media of small particle size as well as pumps that deliver constant flow rates at high pressures has enabled investigators to perform rapid, high resolution liquid chromatography for more than two decades. Studies initiated in this laboratory in 1975, evaluating the compatibility of unprotected peptides with commercially available chromatographic supports and development of solvent systems ultimately led to separations not previously observed with both synthetic peptides and native peptides from tissue extracts. It was rapidly realized however, that recovery of certain molecules could be problematic. To meet the challenges presented by the isolation of natural hormones (such as corticotropin releasing factor and growth hormone releasing hormone) and proteins (such as inhibin and activin) and the need for large quantities of highly purified peptides for clinical investigations, our group invested heavily in identifying new supports (high carbon loading and 300 A pore sizes) and solvent systems (triethylammonium phosphate and trifluoroacetic acid) compatible with reverse phase, size exclusion and ion exchange chromatographies from a practical and economical perspective. More recently, we have contributed to the identification of unusual buffer systems (inclusive of organic modifiers) compatible with capillary zone electrophoresis that will both modulate the capillaries' selectivity, increase resolution and serve as an orthogonal approach to determining peptide purity. From a pragmatic point of view, in this paper we highlight the original and timely contributions (technical and strategical) of this laboratory in the field of analytical and preparative high performance liquid chromatography and capillary zone electrophoresis of synthetic and native biologically active peptides and proteins over the past twenty years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695761     DOI: 10.1002/(SICI)1097-0282(1996)40:3%3C265::AID-BIP2%3E3.0.CO;2-U

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  12 in total

1.  SST3-selective potent peptidic somatostatin receptor antagonists.

Authors:  J C Reubi; J C Schaer; S Wenger; C Hoeger; J Erchegyi; B Waser; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.

Authors:  Manoj P Samant; Doley J Hong; Glenn Croston; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

3.  A uniquely selective inhibitor of the mammalian fetal neuromuscular nicotinic acetylcholine receptor.

Authors:  Russell W Teichert; Jean Rivier; Josep Torres; John Dykert; Charleen Miller; Baldomero M Olivera
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

4.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

6.  Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.

Authors:  Christy Rani R Grace; Judit Erchegyi; Steven C Koerber; Jean Claude Reubi; Jean Rivier; Roland Riek
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

7.  Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.

Authors:  Judit Erchegyi; Renzo Cescato; Christy Rani R Grace; Beatrice Waser; Véronique Piccand; Daniel Hoyer; Roland Riek; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

8.  Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.

Authors:  Christy Rani R Grace; Judit Erchegyi; Manoj Samant; Renzo Cescato; Veronique Piccand; Roland Riek; Jean Claude Reubi; Jean E Rivier
Journal:  J Med Chem       Date:  2008-04-12       Impact factor: 7.446

9.  Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.

Authors:  Judit Erchegyi; Christy Rani R Grace; Manoj Samant; Renzo Cescato; Veronique Piccand; Roland Riek; Jean Claude Reubi; Jean E Rivier
Journal:  J Med Chem       Date:  2008-04-12       Impact factor: 7.446

10.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

Authors:  Renzo Cescato; Judith Erchegyi; Beatrice Waser; Véronique Piccand; Helmut R Maecke; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2008-06-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.